BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33773991)

  • 1. Comparison of Biocartis IDYLLA ™ cartridge assay with Qiagen GeneReader NGS for detection of targetable mutations in EGFR, KRAS/NRAS, and BRAF genes.
    Haiduk T; Brockmann M; Tillmann RL; Pieper M; Lüsebrink J; Schildgen V; Schildgen O
    Exp Mol Pathol; 2021 Jun; 120():104634. PubMed ID: 33773991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
    Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid clinical mutational testing of
    Van Haele M; Vander Borght S; Ceulemans A; Wieërs M; Metsu S; Sagaert X; Weynand B
    J Clin Pathol; 2020 Jan; 73(1):35-41. PubMed ID: 31296605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Idylla
    Makutani Y; Sakai K; Yamada M; Wada T; Chikugo T; Satou T; Iwasa Y; Yamamoto H; de Velasco MA; Nishio K; Kawamura J
    Int J Clin Oncol; 2022 Jul; 27(7):1180-1187. PubMed ID: 35474548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rapid Idylla™ mutational testing: Current and future theranostic applications].
    Bourhis A; Remoué A; Samaison L; Uguen A
    Ann Pathol; 2022 Jul; 42(4):329-343. PubMed ID: 34991924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of
    Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
    J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue.
    Zekri J; Baghdadi MA; Alardati H; Khallaf H; Kabanja JH
    Exp Mol Pathol; 2019 Oct; 110():104270. PubMed ID: 31207216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.
    Franczak C; Witz A; Geoffroy K; Demange J; Rouyer M; Husson M; Massard V; Gavoille C; Lambert A; Gilson P; Gambier N; Scala-Bertola J; Merlin JL; Harlé A
    PLoS One; 2020; 15(1):e0227294. PubMed ID: 31940389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drastic Reduction of Turnaround Time After Implementation of a Fully Automated Assay for RAS-BRAF Mutations in Colorectal Cancer: A Pilot Prospective Study in Real-life Conditions.
    Rossat S; Perrier H; Lefevre M; Louvet C; Le Berre N; Chamois J; Dorel M; Vacque D; Guillaudeau A; Genet D; Maillet E; Triby S; Sabourin JC
    Pathol Oncol Res; 2020 Oct; 26(4):2469-2473. PubMed ID: 32572821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
    Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
    Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorectal Cancer.
    Tsongalis GJ; Al Turkmani MR; Suriawinata M; Babcock MJ; Mitchell K; Ding Y; Scicchitano L; Tira A; Buckingham L; Atkinson S; Lax A; Aisner DL; Davies KD; Wood HN; O'Neill SS; Levine EA; Sequeira J; Harada S; DeFrank G; Paluri R; Tan BA; Colabella H; Snead C; Cruz-Correa M; Ramirez V; Rojas A; Huang H; Mackinnon AC; Garcia FU; Cavone SM; Elfahal M; Abel G; Vasef MA; Judd A; Linder MW; Alkhateeb K; Skinner WL; Boccia R; Patel K
    Am J Clin Pathol; 2020 Jul; 154(2):266-276. PubMed ID: 32525522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
    Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M
    BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
    Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
    PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.
    Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation.
    Gilson P; Franczak C; Dubouis L; Husson M; Rouyer M; Demange J; Perceau M; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(7):e0219204. PubMed ID: 31265477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
    Haley L; Tseng LH; Zheng G; Dudley J; Anderson DA; Azad NS; Gocke CD; Eshleman JR; Lin MT
    Mod Pathol; 2015 Oct; 28(10):1390-9. PubMed ID: 26226847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validating a fully automated real-time PCR-based system for use in the molecular diagnostic analysis of colorectal carcinoma: a comparison with NGS and IHC.
    Colling R; Wang LM; Soilleux E
    J Clin Pathol; 2017 Jul; 70(7):610-614. PubMed ID: 28292978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique.
    Kriegsmann M; Arens N; Endris V; Weichert W; Kriegsmann J
    Diagn Pathol; 2015 Jul; 10():132. PubMed ID: 26220423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.